What Transformation Has the Liver Diseases Therapeutics Market Undergone?
The liver diseases therapeutics market has seen considerable growth due to a variety of factors.
• The market size for therapeutics in liver diseases has witnessed significant growth over the recent years. It is projected to increase from $14.16 billion in 2024 to $15.23 billion in 2025, at a compound annual growth rate (CAGR) of 7.6%. Factors contributing to this growth during the historical period include the high incidence of liver diseases, patterns of alcohol consumption, advances in diagnostic techniques, obesity and metabolic syndrome, awareness campaigns, and screening programs, as well as government efforts to control hepatitis.
What Are The Predictions for The Liver Diseases Therapeutics Market Size?
The Liver Diseases Therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations forecast robust expansion in the liver diseases therapeutics market size in the ensuing years. Projected growth is pegged at $20.78 billion by 2029, with a compound annual growth rate (CAGR) of 8.1%.
The anticipated growth during this period is attributed to factors like precision medicine methods, advances in RNA therapeutics, emphasis on fibrosis treatments, patient advocacy, support groups, development of hepatitis vaccines, and regulatory support for rare drugs. The forecast period will witness key trends such as advancements in hepatitis c treatment, the emergence of new therapies for liver fibrosis, exploration of immunotherapies, application of telemedicine and remote monitoring, and a focus on nutritional interventions.
Which Drivers Are Accelerating Growth In The Liver Diseases Therapeutics Market?
The growth of the liver disease therapeutics market is anticipated to be fueled by the increasing incidence of liver ailments. Therapies for liver disease, which refers to any disorder affecting the liver, aid in the treatment of these diseases through a variety of treatments. For example, the Office for Health Improvement and Disparities, a government agency based in the UK, reported in April 2024 that in 2022, the death rate from liver disease in individuals aged under 75 in England increased to 21.4 per 100,000 population. Notably, there were 6,664 premature deaths among men compared to 3,929 in women. The escalating occurrence of liver diseases is therefore propelling the growth of the liver disease therapeutics market.
What Are The Core Segments Of The Global Liver Diseases Therapeutics Market?
The liver diseases therapeutics market covered in this report is segmented –
1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer
2) By Treatment: Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents, Corticosteroids
3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users
Subsegments:
1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D
2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver
3) By Alcohol-Induced Liver Disease: Alcoholic Hepatitis, Alcoholic Cirrhosis
4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Pre-Book The Liver Diseases Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Liver Diseases Therapeutics Market Size?
The increasing emergence of strategic alliances is a vital trend in the liver disease therapeutics market. Key businesses are forging collaborations in this market to bolster their standing. For example, Aligos Therapeutics Inc., a clinical-stage biopharmaceutical company based in the US, entered into a partnership with Merck & Co, a US company also operating in the liver disease therapeutics space, in January 2022. The focus of this partnership is on the discovery and development of oligonucleotide treatments for non-alcoholic steatohepatitis.
Who Are the Key Players In The Liver Diseases Therapeutics Market?
Major companies operating in the liver diseases therapeutics market include:
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG
• Merck & Co. Inc.
• Novartis AG
• GlaxoSmithKline PLC
• Abbott Laboratories Inc.
• Pfizer Inc.
• Sanofi SA
• Johnson & Johnson Services Inc.
• Bayer AG
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Valeant Pharmaceuticals
• Watson Pharmaceuticals Inc.
• AstraZeneca PLC
• Gilead Sciences Inc.
• Endo International PLC
• Alnylam Pharmaceuticals Inc.
• Provectus Biopharmaceuticals Inc.
• Intercept Pharmaceuticals Inc.
• Conatus Pharmaceuticals Inc.
• CymaBay Therapeutics Inc.
• Viking Therapeutics Inc.
• Madrigal Pharmaceuticals Inc.
• NGM Biopharmaceuticals Inc.
• Arrowhead Pharmaceuticals Inc.
• Dicerna Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Enanta Pharmaceuticals Inc.
What Are The Regional Insights Into The Liver Diseases Therapeutics Market?
North America was the largest region in the liver diseases therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
